**Barclays Initiates Coverage of Ligand Pharmaceuticals with Overweight Rating**
On September 25, 2026, Barclays initiated coverage of Ligand Pharmaceuticals Incorporated (OTCPK:LGNDZ) with an “Overweight” recommendation. This follows a series of supportive actions from other firms; HC Wainwright & Co. reiterated a “Buy” rating on September 24, and Citigroup maintained its “Buy” rating on September 23.
The broader analyst consensus reflects a total of 16 recommendations as of September 1, 2026, with 7 strong buys, 8 buys, and 1 hold, resulting in a positive percentage of 93.8%. However, a significant drop in target prices was noted, with the current mean target at $0.00, down 76.23% from $0.01 earlier this year. Ligand Pharmaceuticals specializes in the development and licensing of biopharmaceutical technologies, with a notable focus on its Captisol technology, which enhances drug formulation.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
